Intermittent radioligand therapy with Lu-177-PSMA-617 in metastatic castration-resistant prostate cancer patients with favorable characteristics and early response

被引：0
|
作者：
Mader, N. [1 ]
Ngoc, C. Nguyen [1 ]
Baumgarten, J. [1 ]
Groener, D. [1 ]
Davis, K. [1 ]
Wichert, J. [1 ]
Tselis, N. [2 ]
Mandel, P. [3 ]
Gruenwald, F. [1 ]
Sabet, A. [1 ]
机构：
[1] Univ Hosp Frankfurt, Dept Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Dept Radiooncol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-988
引用
收藏
页码：S491 / S492
页数：2
相关论文
共 50 条
  • [31] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [32] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Alexander Heinzel
    Dima Boghos
    Felix M. Mottaghy
    Florian Gaertner
    Markus Essler
    Dirk von Mallek
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1054 - 1062
  • [33] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [34] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [35] Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
    Robin Wrenger
    Michael Jüptner
    Marlies Marx
    Yi Zhao
    Maaz Zuhayra
    Amke Caliebe
    Daniar Osmonov
    Ulf Lützen
    BMC Urology, 22
  • [36] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
  • [37] Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer
    Tann, Mark
    Sims, Justin
    Auxier, Ashleigh
    Althouse, Sandra K.
    Salous, Tareq
    King, Jennifer
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 135 - 135
  • [38] Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
    Wrenger, Robin
    Juptner, Michael
    Marx, Marlies
    Zhao, Yi
    Zuhayra, Maaz
    Caliebe, Amke
    Osmonov, Daniar
    Lutzen, Ulf
    BMC UROLOGY, 2022, 22 (01)
  • [39] Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
    Mader, Nicolai
    Groener, Daniel
    Tselis, Nikolaos
    Banek, Severine
    Nagarajah, James
    Grunwald, Frank
    Sabet, Amir
    CANCERS, 2021, 13 (16)
  • [40] Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
    Rahbar, Kambiz
    Bode, Axel
    Weckesser, Matthias
    Avramovic, Nemanja
    Claesener, Michael
    Stegger, Lars
    Boegemann, Martin
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 522 - 528
12345